Using imiquimod for genital warts in female patients

Journal of Women's Health

Volumn 13, Issue 3, 2004, Pages 265-271

  Cox, J Thomas ^a   Petry, Karl Ulrich ^b   Rylander, Eva ^c   Roy, Michel ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c DANDERYD HOSPITAL   (Sweden)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; FLUOROURACIL; IMIQUIMOD; PODOPHYLLIN; PODOPHYLLOTOXIN; TRICHLOROACETIC ACID;

ANXIETY; BURNING SENSATION; CARBON DIOXIDE LASER; CELLULAR IMMUNITY; CONDYLOMA; CRYOTHERAPY; DEPRESSION; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EDEMA; ELECTROSURGERY; EPITHELIUM; EROSION; ERYTHEMA; FEMALE; FEMALE GENITAL TRACT INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INOCULATION; PAIN; PRIORITY JOURNAL; PRURITUS; RECURRENCE RISK; RECURRENT INFECTION; REVIEW; SCAR FORMATION; SEXUAL INTERCOURSE; SEXUALLY TRANSMITTED DISEASE; SHAME; SKIN IRRITATION; SKIN MANIFESTATION; SOCIAL PSYCHOLOGY; SYMPTOMATOLOGY; ULCER; VIRUS LOAD; WART VIRUS;

ADMINISTRATION, TOPICAL; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CONDYLOMATA ACUMINATA; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; INTERFERON INDUCERS; PAPILLOMAVIRIDAE; QUALITY OF LIFE; RECURRENCE; RISK FACTORS; VIRAL LOAD; VULVAR NEOPLASMS; WOMEN'S HEALTH;

EID: 2442665183     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/154099904323016428     Document Type: Review

References (43)

1. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988;10:122.
2. Jablonska S, Majewski S. Human papillomavirus infection in women. Special aspects of infectious diseases in women. Clin Dermatol 1997;15:67.
3. Gall SA. Female genital warts: Global trends and treatments. Infect Dis Obstet Gynecol 2001;9:149.
4. Centers for Disease Control and Prevention. 1998 guidelines for treatment of sexually transmitted diseases. MMWR 1998;47:1.
5. Simms I, Fairley CK. Epidemiology of genital warts in England and Wales: 1971 to 1994. Genitourin Med 1997;73:365.
6. Syrjanen K, Yliskoski M, Kataja V, et al. Prevalence of genital human papillomavirus infections in a mass-screened Finnish female population aged 20-65 years. Int J STD AIDS 1990;1:410.
7. Kjaer SK, Lynge E. Incidence, prevalence and time trends of genital HPV infection determined by clinical examination and cytology. IARC Sci Publ 1989;94: 113.
8. Franco EF. Epidemiology of anogenital warts and cancer. Obstet Gynecol Clin North Am 1996;23:597.
9. Habel LA, Van Den Eeden SK, Sherman KJ, McKnight B, Stergachis A, Daling JR. Risk factors for incident and recurrent condylomata acuminata among women. A population-based study. Sex Transm Dis 1998; 25:285.
10. Karlsson R, Jonsson M, Edlund K, et al. Lifetime number of partners as the only independent risk factor for human papillomavirus infection: A population-based study. Sex Transm Dis 1995;22:119.
11. Bentley E, Jenkins D. Editorial. Papillomavirus Rep 2003:13:145.
12. Schoultz DA, Koutsky LA, Galloway DA. Epidemiology and modes of transmission. In: Gross G, von Krogh G, eds. Human papillomavirus infections in dermato-venereology. London: CRC Press 1997:83.
13. Alloub MI, Barr BB, McLaren KM, Smith IW, Bunney MH, Smart GE. Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. Br Med J 1989;298:153.
14. Ferenczy A. External genital human papillomavirus infections. Curr Obstet Gynaecol 1995;5:98.
15. Schneider A. Natural history of genital human papillomavirus infections. Intervirology 1994;37:201.
16. Clarke P, Ebel C, Catotti DN, Stewart S. The psychosocial impact of human papillomavirus infection: Implications for health care providers. Int J STD AIDS 1996;7:197.
17. Filiberti A, Tamburini M, Stefanon B, et al. Psychological aspects of genital human papillomavirus infection: A preliminary report. J Psychosom Obstet Gynaecol 1993;14:145.
18. Reitano M. Counselling patients with genital warts. Am J Med 1997;102:38.
19. Coleman N, Birley HD, Renton AM, et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994;102:768.
20. Beutner KR, Ferenczy A. Therapeutic approaches to genital warts. Am J Med 1997;102:28.
21. Kraus SJ, Stone KM. Management of genital infection caused by human papillomavirus. Rev Infect Dis 1990;12:620.
22. Duus BR, Philipsen T, Christensen JD, Lundvall F, Sondergaard J. Refractory condylomata acuminata: A controlled clinical trial of carbon dioxide laser versus conventional surgical treatment. Genitourin Med 1985;61:59.
23. von Krogh G, Lacey CJN, Gross G, Barrasso R, Schneider A. European course on HPV associated pathology: Guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 2000;76:162.
24. von Krogh G, Lacey CJN, Gross G, Barrasso R, Schneider A. European guideline for the management of anogenital warts. Int J STD AIDS 2001;12:40.
25. Pride GL. Treatment of large lower genital tract condylomata acuminata with topical 5-fluorouracil. J Reprod Med 1990;35:384.
26. 2 laser for treatment of vaginal condylomata. Obstet Gynecol 1984;64:773.
27. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR 2002;51:RR6.
28. Friedman-Kien AE, Eron LJ, Conant M, et al. Natural interferon α for treatment of condylomata acuminata. JAMA 1988; 259:533.
29. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998;134:25.
30. Garland SM, Sellors W, Wikstrom A, et al. Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts - Results of an open-label, multicenter Phase IIIB trial. Int J STD AIDS 2001;12:722.
31. Wagman FA, Estape RE, Angioli R, Penalver MA. Self-administered topical 5% imiquimod cream for external anogenital warts in adolescent girls. Obstet Gynecol 2001;97:S14.
32. O'Mahony C, Law C, Gollnick HPM, Marini M. New patient-applied therapy for ano-genital warts is rated favorably by patients. Int J STD AIDS 2001;12:565.
33. Ferenczy A, Edwards L, Owens ML, Fox TL. Imiquimod 5% cream is effective and safe in the treatment of genital/perianal warts in female patients. Abstract Book. Philadelphia: Annual Clinical Meeting, American College of Obstetricians and Gynecologists, 1999.
34. Sauder DN, Skinner RB, Fox TL, Owens ML. Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations. Sex Transm Dis 2003;30:124.
35. Stanley MA. Mechanism of action of imiquimod. Papillomavirus Rep 1999;10:23.
36. Arany I, Tyring SK, Stanley MA, et al. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antivir Res 1999;43:55.
37. Schiffman MH, Burk RD. Human papillomaviruses. In: Evans AS, Kaslow R, eds. Viral infections of humans, 4th ed. New York: Plenum Press, 1995:345.
38. Davis G, Wentworth J, Richard J. Self-administered topical imiquimod treatment of vulvar intraepithelial neoplasia. A report of 4 cases. J Reprod Med 2000;45:619.
39. van Seters M, Fons G, van Beurden M. Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3. Results of a pilot study. J Reprod Med 2002;47:701.
40. Jayne CJ, Kaufman RH. Treatment of vulvar intraepithelial neoplasia 2/3 with imiquimod. J Reprod Med. 2002;47:395.
41. Todd RW, Etherington IJ, Luesley DM. The effects of 5% imiquimod cream on high-grade vulval intraepithelial neoplasia. Gynecol Oncol 2002;85:67.
42. Kaufman RAH. Intraepithelial neoplasia of the vulva. Gyneocol Oncol 1995;56:8.
43. Roy M, Postgraduate Supplement: Chronicle of skin and allergy. Chronicle Information Resources, Publishers. Ontario, Canada. February 2001.